Ghassan S. Safadi, M.D., FAAAAI
Dr. Safadi, a graduate of the University of Jordan, completed his postgraduate training in adult and pediatric Allergy and immunology and General Pediatrics at the Cleveland Clinic Foundation in Cleveland, Ohio. He is the recipient of the 1991 Graduate Level-One Award from the Cleveland Clinic Foundation in recognition of being an outstanding first year resident, identified by his peers, for personal and professional qualities beyond the ordinary.
Dr. Safadi is certified by the American Board of Allergy and Immunology (a combined board of the American Board of Pediatrics and the American Board of Internal Medicine) and the American Board of Pediatrics. Dr. Safadi is a Fellow of the American College of Allergy and Immunology, and a Member of the Ohio State Medical Association, American Medical Association, and Academy of Medicine of Toledo.
Following his training in Cleveland, Dr. Safadi served as Assistant Professor and Residency Program Director of Pediatrics at the University of Jordan for three years before relocating to the Toledo area in 2000 where he resides with his wife and three children.
Boards & Certifications
American Board of Allergy & Immunology
Adults & Pediatrics
American Board of Pediatrics
Certified Pollen & Mold Counter, National Allergy Bureau
Publications & Research
Kim K.T., Safadi G.S. Relation of latex specific IgE titer and symptoms in patients allergic to latex. Journal of Allergy & Clinical Immunology 1999; 103 (4): 671-77.
Kim, K.T., Graves, P.B., Safadi, G.S. Implementation recommendations for making health care facilities latex safe. AORN Journal 1998; 67:615-632.
Kim, K.T., Safadi, G.S., Sheikh, K. Diagnostic evaluation of Type I latex allergy. Annals of Allergy, Asthma & Immunology 1998; 80: 66-70.
Aamir R., Safadi, G.S., Cornish, K., Melton, A.L., Wagner, W.O., Battisto, J.R. Shared IgE-binding epitopes in latex. International Archives of Allergy & Immunology 1996; 111(1): 48-54.
Safadi, G.S., Corey, E.C., Taylor, J.S., Wagner, W.O., Pien, L.C., Melton, A.L. Latex hypersensitivity in emergency medical service providers. Annals of Allergy, Asthma & Immunology 1996; 77(1): 39-42.
Terezhalmy G.T., Esposito, S.J., Safadi, G.S. Immunopharmacology. Dental Clinics of North America 1996; 40(1): 685-707.Aamir, R., Safadi, G.S., Mandelik, J.A., Cornish, K., Melton, A.L., Wagner, W.O., Battisto, J.R. Guinea pig: an animal model for latex hypersensitivity. International Archives of Allergy & Immunology 1996; 110: 187-194.
Safadi, G.S., Safadi, T.J., Terezhalmy, G.T., Taylor, J.S., Battisto, J.R., Melton, A.L. Latex hypersensitivity: its prevalence among dental professionals. Journal of the American Dental Association 1996; 127(1): 83-88.
Safadi, G.S., Corey, E.C. Danger lurks in latex. Emergency 1995; 27(10): 56-61.
Safadi, G.S. Computer Software, Pediatric cough & fever: an exercise in clinical problem solving. Clinical Pediatrics [Book Review] 1990; 30(6): 390.
1994, 1995 American College of Allergy, Asthma & Immunology
1993 American Academy of Allergy, Asthma & Immunology
1992 Cleveland Clinic Pediatric Resident
Research Day Award
1991 American Society for Pediatric Research
1990 The Cleveland Clinic Foundation Graduate-Level
One Alumni Association Award
1985 University of Jordan
1987 University of Jordan
M.B.B.S. Degree in Medicine and Surgery
1987-1988 Jordan University Hospital
Pediatric Rotating Internship
1988-1989 Jordan University Hospital
General Pediatric Residency
1989-1992 Cleveland Clinic Foundation
General Pediatric Internship & Residency
1992-1993 Cleveland Clinic Foundation
Pediatric Chief Resident
1993-1996 Cleveland Clinic Foundation
Adult & Pediatric Allergy & Immunology
December 2003 - Present
Dr. Safadi & Associates, Inc.
2000 - November 2003
Dr. Winder & Associates, Inc
1997 - 2000
Assistant Professor of Pediatrics & Allergy & Immunology
University of Jordan
Amman - Jordan
Cerified Pollen & Mold Counter, National Allergy Bureau, American Academy of Allergy, Asthma & Immunology
Fellow, American Academy of Allergy, Asthma & Immunology
Fellow, American College of Allergy, Asthma & Immunology
Joint Council of Allergy, Asthma & Immunology
American Medical Association
Ohio State Medical Association
Academy of Medicine of Toledo & Lucas County
1. Mechanisms to reduce latex hypersensitivity. [RPC # 5125]. Approved for internal funding by the Cleveland Clinic Research Protocol Committee August 1995.
2. Phase III, Multicenter, Clinical study to document performance of the prototype Non ammoniated latex as a diagnostic testing material (John Hopkins-IND# 4920. [IRB 1147]. Approved by the Cleveland Clinic Institutional Review Board April 1995
3. Latex Hypersensitivity: I. a study of the level of awareness and prevalence of latex hypersensitivity among Emergency Medical Workers in the city of Cleveland. II. Determination of the allergenic protein(s) in latex. [RPC # 4902]. Approved for internal funding by the Cleveland Clinic Research Protocol Committee November 1994
4. Latex Hypersensitivity: Determination of prevalence in a population of health care workers, and determination of the allergenic protein(s) in latex. [RPC # 4429] Approved for internal funding by the Cleveland Clinic Research Protocol Committee January 1994
5. Establishing two animal models (mouse and guinea pig) for latex hypersensitivities: Immediate (Type I) and delayed (Type IV). [RPC # 4435] Approved for internal funding by the Cleveland Clinic Research Protocol Committee August 1993
6. Production of antibodies to soluble components of latex in rabbits. [RPC #4232] Approved for internal funding by the Cleveland Clinic Research Protocol Committee January 1993
7. Studying the effect of Interleukins 2, 4 and 10 on the Development of Cytotoxic T lymphocytes and lymphokine activated killer cells in vitro. [RPC #3869] Approved for internal funding by the Cleveland Clinic Research Protocol Committee January 1992
1. A randomized, double-blind, placebo-controlled, parallel group study of four doses of … as an open active-control in the treatment of adults and adolescents with allergic rhinitis induced by grass pollen, Muro Pharmaceuticals, Inc
2. Screening protocol to identify subjects who exhibit difficulty tolerating a high dose of …, Schering Plough Research Institute.
3. Efficacy & safety of combination… vs. … and placebo in the treatment of subjects with seasonal allergic rhinitis, Schering Plough Research Institute.
4. Efficacy & safety of combination… vs. … and placebo in the treatment of subjects with seasonal allergic rhinitis and a history of perennial allergic rhinitis, Schering Plough Research Institute.
5. Randomized, double-blind…comparison of … vs …. vs placebo in subjects with COPD, GlaxoWellcome.
6. A double-blind… randomized, placebo-controlled… study to assess the safety and efficacy of… in adolescent and adult patients, Dey Laboratories.
7. Chronic-dose comparison of the efficacy and safety of… in mild to moderate asthmatics, Baker Norton Pharmaceuticals.
8. An open, randomized, parallel group, multicenter trial to compare a stratified care treatment regimen based on Migraine Disability (MIDAS grade) versus standard therapy for the acute treatment of migraine headache, Astra Zeneca.
9. An open-label, randomized, multiple dose, parallel, multicenter study of …in the treatment of Gastroesophageal Reflux (GER) symptoms in pediatric subjects age 5 days-18 years
10. Multicenter, double-blind, randomized, parallel group syudy of….vs placebo in patients with asthma, Altana.
11. A 12 week prospective, randomized, double-blind, placebo-controlled, fixed-dose, parallel group study of the safety and efficacy of … bid and … TID in female patients with constipation-predominant irritable bowel syndrome with a 6 month open label extension, Forest Labs.